Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progress in HIV vaccine development.

M I Johnston1, J Flores

  • 1Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892-7628, USA. pjohnston@niaid.nih.gov

Current Opinion in Pharmacology
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Core data set for real world data in multiple sclerosis: customization for latin america from a global task force recommendation].

Revista de neurologia·2024
Same author

Effects of an early rehabilitation program for adult cystic fibrosis patients during hospitalization: a randomized clinical trial.

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas·2023
Same author

Richer than Gold: the fungal biodiversity of Reserva Los Cedros, a threatened Andean cloud forest.

Botanical studies·2023
Same author

Prevalence and duration of symptoms among moderate and severe COVID-19 patients 12 months after discharge.

Internal and emergency medicine·2022
Same author

Mutations in the John Cunningham virus VP1 gene could predispose to the development of progressive multifocal leukoencephalopathy in multiple sclerosis patients undergoing treatment with natalizumab.

Multiple sclerosis and related disorders·2021
Same author

Safety and immunogenicity of two formulations of rotavirus vaccine in Vietnamese infants.

Vaccine·2021
Same journal

Targeting the ischemic cascade: Review on approved and investigational stroke therapies.

Current opinion in pharmacology·2026
Same journal

Senotherapeutic strategies for ovarian aging: Mechanistic insights and translational perspectives.

Current opinion in pharmacology·2026
Same journal

Chrono-immunotherapy in precision oncology: Circadian control of the tumor microenvironment and time-of-day optimization of immune checkpoint blockade.

Current opinion in pharmacology·2026
Same journal

Methotrexate: Integrating molecular pharmacology, systems toxicology, and precision rescue strategies.

Current opinion in pharmacology·2026
Same journal

Acupuncture and non-invasive neuromodulation-induced neuro-endocrine-immune changes associated with the amelioration of depression-like behaviors: A systematic review of animal studies.

Current opinion in pharmacology·2026
Same journal

Alopecia areata: Mechanisms, targeted therapies, and translational challenges.

Current opinion in pharmacology·2026
See all related articles

HIV vaccine development is advancing with new trials and preclinical candidates. While some vaccines show promise in animal models, those inducing broadly neutralizing antibodies are still needed.

Area of Science:

  • Immunology
  • Vaccinology
  • Virology

Background:

  • Significant progress in human immunodeficiency virus (HIV) vaccine research is evident.
  • The preclinical pipeline for HIV vaccines has seen considerable expansion.

Purpose of the Study:

  • To review recent advancements in HIV vaccine development.
  • To highlight the status of preclinical and clinical HIV vaccine candidates.

Main Methods:

  • Review of current HIV vaccine research landscape.
  • Analysis of preclinical data and early-stage clinical trial initiation.

Main Results:

  • First efficacy trials for HIV vaccines have commenced.
  • Preclinical candidates demonstrate robust cellular immunity and protection in non-human primates.

Related Experiment Videos

  • Development of HIV vaccine candidates inducing broadly neutralizing antibodies remains a challenge.

    • Conclusions:

    • The field of HIV vaccine development is progressing with ongoing clinical trials.
    • Preclinical models show success, but achieving broadly neutralizing antibodies is a critical unmet need for effective HIV vaccines.